Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study

Journal:

The Lancet Oncology

Published:

2025-10-12

DOI:

10.1016/s1470-2045(25)00462-0

Affiliations:

15

Authors:

19

Go to article

Institutions	Authors	Share
Kobe Minimally Invasive Cancer Center, Japan	3.066667	0.16
Nagoya Medical Center, Japan	2.066667	0.11
Kyushu Cancer Center, Japan	1.066667	0.06
Kanagawa Cancer Center, Japan	1.066667	0.06
Sendai Kousei Hospital, Japan	1.066667	0.06
Kindai University, Japan	1.066667	0.06
Kurashiki Central Hospital (KCH), Japan	1.066667	0.06
Hyogo Medical University, Japan	1.066667	0.06
Kobe City Medical Center General Hospital, Japan	1.066667	0.06
Kyushu University, Japan	1.066667	0.06
Kyoto University, Japan	1.066667	0.06
Takarazuka City Hospital, Japan	1.066667	0.06
Wakayama Medical University, Japan	1.066667	0.06
Hyogo Prefectural Amagasaki General Medical Center (Hyogo AGMC), Japan	1.066667	0.06
Nagoya City University, Japan	1.066667	0.06

Interested in Oncology and Carcinogenesis?